Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

BACKGROUND: Cabozantinib is an orally available inhibitor of tyrosine kinases including VEGFR2 and c-MET. We performed a post hoc analysis to find associations between select plasma biomarkers and treatment response in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) who r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Leibowitz-Amit, Raya, Pintilie, Melania, Khoja, Leila, Azad, Arun A., Berger, Raanan, Laird, A. Douglas, Aftab, Dana T., Chi, Kim N., Joshua, Anthony M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4712499/
https://ncbi.nlm.nih.gov/pubmed/26762579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0747-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados